# US talc litigation: J&J $5.5B settlement

> Situation record from CLSTR: https://clstr.news/situations/us-talc-litigation-and-womens-product-safety
> Updated: 2026-08-04T09:38:54.000Z. Sources: 47. Developments: 4.

U.S. courts continue to hear large talc lawsuits alleging asbestos in baby powder caused ovarian cancer and mesothelioma. A California jury awarded $966 million to a mesothelioma patient, and manufacturers have set aside roughly $9 billion for liability. The litigation prompted removal of talc baby‑powder from U.S. and Canadian markets in 2020; J&J stopped selling talc‑based baby powder in the United States in 2020 and worldwide in 2023.

Researchers have highlighted tumor risks from injectable contraceptives, linking long‑term high‑dose use to meningiomas, fueling calls for stronger safety standards for women’s products.

In July 2026 Johnson & Johnson announced a voluntary settlement valued at about $5.5 billion to resolve roughly 76,000 ovarian‑cancer claims. The plan requires at least 95 % of eligible claimants to accept; $3 billion would be paid in 2027 with the balance in 2028. J&J maintains its talc is asbestos‑free, does not admit liability, and its litigation vice‑president called the claims “baseless.” The settlement, negotiated outside bankruptcy court, covers only existing suits and would resolve the claims within 18‑24 months if the acceptance threshold is met.

## Claims

- Johnson & Johnson will pay an estimated $5.5 billion to settle talc lawsuits. (reported by 13 sources)
- The settlement aims to resolve about 76,000 ovarian‑cancer claims. (reported by 11 sources)
- The settlement requires participation of at least 95 % of eligible claimants to proceed. (reported by 11 sources)
- The settlement is voluntary and negotiated outside bankruptcy court. (reported by 11 sources)
- Johnson & Johnson will make an initial $3 billion payment in 2027, with the remainder paid by 2028. (reported by 11 sources)
- Johnson & Johnson maintains its talc products are safe and asbestos‑free, denying a causal link to cancer. (reported by 11 sources)
- Three prior attempts to resolve the talc litigation through bankruptcy were rejected by U.S. courts. (reported by 11 sources)
- The settlement does not cover future talc‑related lawsuits. (reported by 11 sources)
- Johnson & Johnson offered a $5.5 billion settlement to resolve talc cancer lawsuits. (reported by 9 sources)
- Johnson & Johnson agreed to pay at least $5.5 billion to settle talc‑related lawsuits. (reported by 6 sources)
- The settlement is expected to resolve claims within 18–24 months. (reported by 6 sources)
- Johnson & Johnson agreed to pay at least $5.5 billion to settle talc lawsuits. (reported by 6 sources)
- The settlement requires at least 95 % of eligible claimants to participate. (reported by 3 sources)
- The settlement is voluntary and not filed through bankruptcy court. (reported by 3 sources)
- Johnson & Johnson previously attempted three bankruptcy filings to resolve the talc litigation, all of which were rejected by US courts. (reported by 3 sources)
- The settlement would cover approximately 76,000 ovarian‑cancer claims. (reported by 3 sources)
- The settlement requires at least 95 % participation of eligible claimants to become effective. (reported by 3 sources)
- The settlement is voluntary and was negotiated outside of bankruptcy court. (reported by 3 sources)
- The settlement covers about 76,000 claims, including federal court cases in New Jersey and related state‑court actions. (reported by 2 sources)
- The settlement requires acceptance by 95% of ovarian‑cancer claimants before it becomes final. (reported by 2 sources)
- Johnson & Johnson expects to pay $3 billion in 2027 with further payments in 2028. (reported by 2 sources)
- Total payout could exceed $7 billion depending on participation levels. (reported by 2 sources)
- Johnson & Johnson previously settled most asbestos‑related talc lawsuits alleging mesothelioma. (reported by 2 sources)
- Erik Haas, J&J’s vice president of litigation, said the claims are meritless. (reported by 2 sources)
- Chris Seeger, representing about 2,500 clients, said the settlement is fair. (reported by 2 sources)
- The settlement covers only existing claims, not future lawsuits. (reported by 2 sources)
- Johnson & Johnson maintains that its talc products are safe and asbestos‑free, denying any link to cancer. (reported by 2 sources)
- The settlement aims to resolve all existing claims within about 18 months. (reported by 2 sources)
- Johnson & Johnson maintains its talc products are safe and asbestos‑free, denying causation of ovarian cancer. (reported by 2 sources)
- Johnson & Johnson will make an initial $3 billion payment next year, with the balance paid by 2028. (reported by 1 source)
- Johnson & Johnson will make an initial $3 billion payment next year, with no further payments before 2028. (reported by 1 source)

## Timeline

### 2026-08-04: Johnson & Johnson offers $5.5 billion settlement to end talc lawsuits

Johnson & Johnson proposes a $5.5 billion settlement covering about 76,000 talc lawsuits, denying liability and awaiting approval from plaintiffs’ counsel.

3 sources. https://clstr.news/cluster/johnson-johnson-offers-55-billion-settlement-to-end-talc-lawsuits

### 2026-07-29: Johnson & Johnson proposes $5.5 billion settlement to end talc cancer lawsuits

Johnson & Johnson offers a $5.5 billion voluntary settlement covering ~76,000 U.S. ovarian‑cancer talc claims, requiring 95% claimant approval, with $3 billion due in 2027 and the rest in 2028.

11 sources. https://clstr.news/cluster/johnson-johnson-reaches-55-billion-talc-settlement-to-end-ovariancancer-lawsuits

### 2026-07-27: Johnson & Johnson to Pay $5.5 B to Settle U.S. Talc Cancer Lawsuits

Johnson & Johnson will pay about $5.5 billion to settle 76,000 U.S. talc lawsuits, pending 95% claimant approval; total payout may exceed $7 billion.

32 sources. https://clstr.news/cluster/johnson-johnson-to-pay-55-b-to-settle-tens-of-thousands-of-talc-lawsuits

### 2026-07-27: US Talc Lawsuits and Birth‑Control Risks Highlight Women's Product Safety

US courts award $966 million in a talc baby‑powder case and highlight ongoing lawsuits, while studies link injectable birth‑control to meningioma risk, prompting calls for stricter product safety.

2 sources. https://clstr.news/cluster/us-talc-lawsuits-and-birthcontrol-risks-highlight-womens-product-safety

---
Cite as: US talc litigation: J&J $5.5B settlement. CLSTR, https://clstr.news/situations/us-talc-litigation-and-womens-product-safety
